Maxim Group restated their hold rating on shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) in a report published on Tuesday.
Several other research firms have also issued reports on RTTR. Chardan Capital set a $5.00 target price on shares of Ritter Pharmaceuticals and gave the company a buy rating in a report on Sunday, February 19th. Aegis reiterated a buy rating on shares of Ritter Pharmaceuticals in a report on Tuesday, March 7th. Finally, Zacks Investment Research lowered shares of Ritter Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, March 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Ritter Pharmaceuticals presently has an average rating of Buy and an average price target of $5.42.
Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 0.62 on Tuesday. Ritter Pharmaceuticals has a 1-year low of $0.55 and a 1-year high of $3.75. The firm’s market capitalization is $7.20 million. The company’s 50-day moving average price is $1.12 and its 200-day moving average price is $2.35.
Ritter Pharmaceuticals (NASDAQ:RTTR) last released its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.24. Equities research analysts expect that Ritter Pharmaceuticals will post ($1.48) earnings per share for the current fiscal year.
In other news, CEO Michael D. Step acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 27th. The stock was bought at an average cost of $2.65 per share, for a total transaction of $26,500.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 49.00% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in the company. Alyeska Investment Group L.P. purchased a new position in shares of Ritter Pharmaceuticals during the fourth quarter worth $1,768,000. Knoll Capital Management LP purchased a new position in shares of Ritter Pharmaceuticals during the third quarter worth $869,000. Finally, Baker BROS. Advisors LP purchased a new position in shares of Ritter Pharmaceuticals during the third quarter worth $672,000. Institutional investors own 9.60% of the company’s stock.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.